Two-Week Aflibercept or Erlotinib Administration Does Not Induce Changes in Intestinal Morphology in Male Sprague-Dawley Rats But Aflibercept Affects Serum and Urine Metabolic Profiles

Richard A. Forsgård; Vannina G. Marrachelli; Jere Linden; Rafael Frias; Maria Carmen Collado; Riitta Korpela; Daniel Monleon; Thomas Spillmann; Pia Österlund

doi:10.1016/j.tranon.2019.04.019

Two-Week Aflibercept or Erlotinib Administration Does Not Induce Changes in Intestinal Morphology in Male Sprague-Dawley Rats But Aflibercept Affects Serum and Urine Metabolic Profiles

Richard A. Forsgård, Vannina G. Marrachelli, Jere Linden, Rafael Frias, Maria Carmen Collado, Riitta Korpela, Daniel Monleon, Thomas Spillmann, Pia Österlund

Research output: Contribution to journal › Article › Scientific › peer-review

Original language	English
Journal	Translational oncology
Volume	12
Issue number	8
Pages (from-to)	1122-1130
Number of pages	9
ISSN	1936-5233
DOIs	https://doi.org/10.1016/j.tranon.2019.04.019
Publication status	Published - Aug 2019
MoE publication type	A1 Journal article-refereed

Fields of Science

METASTATIC COLORECTAL-CANCER
1ST-LINE TREATMENT
ANTITUMOR-ACTIVITY
OXIDATIVE STRESS
BEVACIZUMAB
COMBINATION
CELLS
CHEMOTHERAPY
TOXICITY
ACID
3122 Cancers

Access to Document

10.1016/j.tranon.2019.04.019Licence: CC BY-NC-ND

1-s2.0-S1936523319300439-mainFinal published version, 550 KBLicence: CC BY-NC-ND

Cite this

Forsgård, R. A., Marrachelli, V. G., Linden, J., Frias, R., Carmen Collado, M., Korpela, R., Monleon, D., Spillmann, T., & Österlund, P. (2019). Two-Week Aflibercept or Erlotinib Administration Does Not Induce Changes in Intestinal Morphology in Male Sprague-Dawley Rats But Aflibercept Affects Serum and Urine Metabolic Profiles. Translational oncology, 12(8), 1122-1130. https://doi.org/10.1016/j.tranon.2019.04.019

@article{bd93ef8d435246c3b57090fc6c31316a,

title = "Two-Week Aflibercept or Erlotinib Administration Does Not Induce Changes in Intestinal Morphology in Male Sprague-Dawley Rats But Aflibercept Affects Serum and Urine Metabolic Profiles",

keywords = "METASTATIC COLORECTAL-CANCER, 1ST-LINE TREATMENT, ANTITUMOR-ACTIVITY, OXIDATIVE STRESS, BEVACIZUMAB, COMBINATION, CELLS, CHEMOTHERAPY, TOXICITY, ACID, 3122 Cancers",

author = "Forsg{\aa}rd, {Richard A.} and Marrachelli, {Vannina G.} and Jere Linden and Rafael Frias and {Carmen Collado}, Maria and Riitta Korpela and Daniel Monleon and Thomas Spillmann and Pia {\"O}sterlund",

year = "2019",

month = aug,

doi = "10.1016/j.tranon.2019.04.019",

language = "English",

volume = "12",

pages = "1122--1130",

journal = "Translational oncology",

issn = "1936-5233",

publisher = "EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC",

number = "8",

}

Forsgård, RA, Marrachelli, VG, Linden, J, Frias, R, Carmen Collado, M, Korpela, R, Monleon, D, Spillmann, T & Österlund, P 2019, 'Two-Week Aflibercept or Erlotinib Administration Does Not Induce Changes in Intestinal Morphology in Male Sprague-Dawley Rats But Aflibercept Affects Serum and Urine Metabolic Profiles', Translational oncology, vol. 12, no. 8, pp. 1122-1130. https://doi.org/10.1016/j.tranon.2019.04.019

Two-Week Aflibercept or Erlotinib Administration Does Not Induce Changes in Intestinal Morphology in Male Sprague-Dawley Rats But Aflibercept Affects Serum and Urine Metabolic Profiles. / Forsgård, Richard A.; Marrachelli, Vannina G.; Linden, Jere et al.

In: Translational oncology, Vol. 12, No. 8, 08.2019, p. 1122-1130.

Research output: Contribution to journal › Article › Scientific › peer-review

TY - JOUR

T1 - Two-Week Aflibercept or Erlotinib Administration Does Not Induce Changes in Intestinal Morphology in Male Sprague-Dawley Rats But Aflibercept Affects Serum and Urine Metabolic Profiles

AU - Forsgård, Richard A.

AU - Marrachelli, Vannina G.

AU - Linden, Jere

AU - Frias, Rafael

AU - Carmen Collado, Maria

AU - Korpela, Riitta

AU - Monleon, Daniel

AU - Spillmann, Thomas

AU - Österlund, Pia

PY - 2019/8

Y1 - 2019/8

KW - METASTATIC COLORECTAL-CANCER

KW - 1ST-LINE TREATMENT

KW - ANTITUMOR-ACTIVITY

KW - OXIDATIVE STRESS

KW - BEVACIZUMAB

KW - COMBINATION

KW - CELLS

KW - CHEMOTHERAPY

KW - TOXICITY

KW - ACID

KW - 3122 Cancers

U2 - 10.1016/j.tranon.2019.04.019

DO - 10.1016/j.tranon.2019.04.019

M3 - Article

VL - 12

SP - 1122

EP - 1130

JO - Translational oncology

JF - Translational oncology

SN - 1936-5233

IS - 8

ER -